MedTrace Logo

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization

NCT00291811 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2014-02-11

No results posted yet for this study

Summary

The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant.

Conditions

  • Autologous Stem Cell Transplant

Interventions

DRUG

AMD3100 + G-CSF

Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291811 on ClinicalTrials.gov